Research is at a critical point, particularly as investigators question whether knocking down level of amyloid in patients with an established case of the disease can do any good, therefore, there is a new focus on alternative pathways, including alterations in intracellular signaling with emphasis on prevention techniques and cognitive improvements.
IB-AD: is a product that showed anti-Alzheimer's potential as it is neurogenesis. IB-AD works on both canonical and non-canonical WNT pathways. Clinical trials have demonstrated reduction in inflammation in the brain and prevention of cognitive impairment. IB-AD activates WNT pathway, activates Peroxisome Proliferators, reduces Tau hyperphosphorylation, and stimulates LTP.
Target Indication:
Alzheimer Disease and related cognitive impairments
Route of Administration:
Oral
Mechanism of Action:
- Activates Wnt signaling
- Inhibits GSK-3β
- Reduces tau hyperphosphorylation
- Activates Peroxisome Proliferators
- Induces postsynaptic proteins and synaptic function (LTP)
- Stimulates neurogenesis
Pre-clinical Result:
- IB-AD prevents inflammatory and oxidative damage triggered by the high Aβ deposits
- IB-AD acts on brain neuropathology, learning and memory
- IB-AD alleviates memory decline induced by Aβ deposits by inducing postsynaptic proteins.
- IB-AD activates Wnt pathway and reduces tau phosphorylation.
- IB-AD increases postsynaptic potentials in hippocampal CA1 slices, and prevents Aβ oligomer effects
- IB-AD protects from astrocytic proliferation and protein nitrotyrosination induced by Aβ in a transgenic AD model.
- IB-AD prevents the decrease of synaptic proteins triggered by Aβ oligomers
- IB-AD inhibits GSK-3β, and therefore decreases long-term depression (LTD).
Key Patents and IP Rights
- US Patent Number: 8,084,495: Composition of labdane diterpenes extracted from andrographis paniculata, useful for the treatment of autoimmune diseases, and alzheimer disease by activation for PPR-gamma receptors
- US Patent awarded April 2015, Patent to be published in June 2015: PCT Serial No. US61/814,445: Andrographolide stimulates neurogenesis and is useful for the treatment of cognitive impairment including Alzheimer, Dementia, Parkinson Disease, autism, schizophrenia by activation of the WNT and GSK3 pathways.
Publications:
- Biochem. J. (2015) 466, 415–430: Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo
- Molecular Neurodegeneration (2014), 9:61: RESEARCH ARTICLE Open Access Andrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1 mice